The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Novo Nordisk foundation’s obesity head works as paid adviser to chocolate maker Ferrero
Professor Arne Astrup is also involved in project to change widely-accepted definition of ultra-processed food ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
BioSpace3h
Altimmune To Test Investigational GLP-1–Based Obesity Drug for Alcohol Use Disorder
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Medical Dialogues9h
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
How Much Should Weight Loss Drugs Cost?
A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...
Healio2h
Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...
Labiotech.eu3h
Can GLP-1 agonists help treat addiction?
As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...
StockNews.com Upgrades Novo Nordisk A/S (NYSE:NVO) to Strong-Buy
StockNews.com upgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a strong-buy rating in a report released on Thursday. A number of other analysts have also recently ...